TherapeuticsMD (TXMD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on TherapeuticsMD (TXMD) is Neutral.

The composite score behind that read is -0.03, weighing +0.22 of bullish evidence against -0.37 bearish.

TherapeuticsMD last closed at $2.06, +2.49% on the session.

Against the IVW growth benchmark the position is +1.69% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

20 graded predictions for TXMD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks TherapeuticsMD in the 39th percentile on return on equity, where 100 is best.

TherapeuticsMD is classified under Health Care / Pharmaceuticals, with a market capitalisation of $23.26M.

StockMap tracks TherapeuticsMD as the 121st largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite TherapeuticsMD ranks 69th of 151 in the group, against a group median of -0.08.